IP Library Granted Patent US 10,471,046
Granted Patent B2
US 10,471,046 · App. 14/942,021 · Granted Nov 12, 2019

Method for treating, preventing, or reducing the risk of skin infection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,471,046
App. No.
14/942,021
Granted
Nov 12, 2019
Kind
B2
Abstract

The present invention relates to methods for treating acne and other skin infections caused or mediated by Propionibacterium acnes, Gardnerella vaginalis , or Staphylococcus aureus in a patient with a safe and effective amount of a topically applied oxazolidinone antibiotic compound.

Claims (22)

1. A method of treating a skin infection caused or mediated by Propionibacterium acnes or Gardnerella vaginalis in a patient, the method comprising administering a pharmaceutically effective amount of a compound having the formula:

or a pharmaceutically acceptable tautomer, salt, ester, or prodrug thereof.

2. The method according to claim 1 , wherein the compound is a pharmaceutically acceptable salt selected from the group consisting of acetate, ascorbate, benzoate, citrate, esylate, ethanedisulfonate, fumarate, hydrochloride, lactate, maleate, mesylate, phosphate, pyroglutamate, salicylate, succinate, sulfate, tartrate, and tosylate.

3. The method according to claim 1 , wherein the skin infection is caused or mediated by Propionibacterium acnes.

4. The method according to claim 1 , wherein the skin infection is caused or mediated by Gardnerella vaginalis.

5. The method according to claim 1 , wherein the skin infection is selected from acne vulgaris, bacterial conjunctivitis, and bacterial vaginosis.

6. The method according to claim 1 , wherein the skin infection is acne vulgaris.

7. The method according to claim 1 , wherein the skin infection is bacterial vaginosis.

8. The method according to claim 1 , wherein the compound is administered orally, parenterally, or topically.

9. The method according to claim 1 , wherein the compound is administered topically.

10. The method according to claim 1 , wherein the patient is a mammal or domestic animal.

11. The method according to claim 1 , wherein the patient is a human.

12. The method according to claim 1 , wherein the compound is administered once daily or twice daily.

13. The method according to claim 1 , wherein the compound is administered once daily.

14. The method according to claim 1 , wherein the compound is administered twice daily.

15. A method of treating a skin infection caused or mediated by Propionibacterium acnes or Gardnerella vaginalis in a patient, the method comprising administering a pharmaceutically effective amount of a topical formulation comprising one or more dermatologically acceptable carriers and a compound having the formula:

or a pharmaceutically acceptable tautomer, salt, ester, or prodrug thereof.

16. The method according to claim 15 , wherein the skin infection is caused or mediated by Propionibacterium acnes.

17. The method according to claim 15 , wherein the skin infection is caused or mediated by Gardnerella vaginalis.

18. The method according to claim 15 , wherein the skin infection is selected from acne vulgaris, bacterial conjunctivitis, and bacterial vaginosis.

19. The method according to claim 15 , wherein the skin infection is acne vulgaris.

20. The method according to claim 15 , wherein the skin infection is bacterial vaginosis.

Assignments (5)
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 061314/0572 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 22, 2020
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 054836/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 048030/0489 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2015
From: DUFFY, ERIN M
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 037226/0932 →